Revolution Medicines' Approval Won the Hard Part. The Stock Price Is Betting on the Rest

On August 26, the FDA approved Revolution Medicines' RASONQUE (daraxonrasib) for a form of cancer that has historically defeated every drug thrown at it: previously treated metastatic pancreatic cancer. It is the first targeted therapy to attack a genetic driver of the disease, and the data weren't marginal — the drug roughly doubled patients' median survival and cut the risk of death by 60%. Two weeks later, with the stock already up about 156% for the year, Morgan Stanley initiated coverage as Overweight and made a provocative argument: the approval is only the foundation. The real upside, the bank says, is "drug expansion and new combination therapies" still sitting in the clinic.

The bulls and bears agree on the facts. They are fighting over what those facts are worth at a roughly $43.6 billion market capitalization.

The shared record

As of September 10, 2026, RVMD trades near $203, up from a 52-week low of about $42 and a rolling-year gain of roughly 335%. The company has no meaningful revenue yet — it is a clinical-stage oncology company that just became commercial. The approval is real and fully documented: in the Phase 3 RASolute 302 trial, daraxonrasib delivered median overall survival of 13.2 months versus 6.7 months on chemotherapy, a hazard ratio of 0.40, and median progression-free survival of 7.3 months versus 3.5. At 12 months, 53.3% of treated patients were alive versus 18.7% on the control arm.

The commercial base is small, though. The label covers adults with metastatic pancreatic adenocarcinoma who've had at least one prior therapy — a serious but comparatively narrow population. Recent wholesale acquisition cost is set at $39,800 for a 30-day supply. The company ended the second quarter with $3.9 billion in cash and investments, but it burned a $644 million net loss that quarter (including a $151 million non-cash warrant charge) and spent about $505 million on operations, nearly all of it on R&D. In other words: the balance sheet funds years of work, but the current business loses money, and the whole $40 billion-plus valuation rides on what happens next.

Round one: the proof already in hand

The bull's strongest point isn't the survival number — it's what that number implies about the whole platform. Daraxonrasib is an oral inhibitor of the "RAS(ON)" form of mutant RAS, the protein family mutated in a large share of pancreatic, lung, and colorectal cancers, long written off as undruggable. The company's tri-complex platform aims to hit multiple RAS variants and indications with one scaffold. RASONQUE showing a 0.40 hazard ratio in the hardest RAS-addicted cancer is, the bull argues, de-risking evidence for everything else the platform touches.

The bear's concession is real but narrower: yes, the drug works, and that fight is over. But a pivotal trial in second-line pancreatic cancer proves that one molecule works in one patient group. It says little about whether the same chemistry dominates first-line pancreatic, lung, or colorectal cancer, where competition is heavier and biology differs.

Round one to the bull on the question "is the platform real?" — the evidence margin is decisive. But the approval was priced months ago; the stock nearly quadrupled in value before the FDA even signed off. That win is in the number.

Round two: the expansion and combinations

Morgan Stanley's target — $255, against a consensus "strong buy" with Street targets from $179 to $320 — rests mainly on what it calls the "most important next value driver": zoldonrasib, a G12D-selective drug. In KRAS G12D non-small-cell lung cancer, zoldonrasib plus standard therapy posted a 52% confirmed response rate and 11.1-month median progression-free survival in Phase 1/2 data. The company is running a broad web of Phase 3 trials: daraxonrasib in first-line pancreatic (RASolute 303) and the adjuvant setting (RASolute 304), zoldonrasib combinations in pancreatic (RASolute 305 and 309), and a suite of lung-cancer studies (RASolve 301, 307, 308) across RAS mutation types. Truist has floated $2.3 billion in sales by 2028 if first-line expansion lands.

This is the bull's real case, and it is coherent: a de-risked first approval, a cash runway measured in years, and several shots at much larger markets, with partnerships from Bristol Myers Squibb and others helping spread the R&D cost.

The bear's answer is that all of that optionality is already selling — this is the part of the story the price has begun to pay for. First-line and lung readouts are still one to three years away, and they arrive in a crowding field. Amgen already owns an approved KRAS G12C lung drug. The G12D space that zoldonrasib targets is drawing direct rivals, and Revolution is currently in a patent-infringement fight with Erasca over a competing molecule — a dispute that at minimum distracts and could, at worst, complicate the franchise. In promising-but-small Phase 1/2 data, the bear says, we have seen 82% response rates before; the durable question is whether these combos hold in thousands of randomized patients, not dozens.

Round two splits. The bull wins the breadth of the opportunity; the bear wins the timing. Every marquee expansion trial still has to read out.

What the price demands

Now make both stories pay rent. The bull's full-envelope scenario — first-line pancreatic plus lung across multiple RAS variants — plausibly supports a large, durable, multi-billion-dollar franchise, which is how a $43 billion company is routinely justified. The bear's scenario — second-line pancreatic only, with the expansion path contested and years away — supports a business worth a small fraction of that.

At $203, the market is not paying for RASONQUE in second-line pancreatic. It is paying for the expansion and combination story to work largely as advertised. That is a reasonable bet on a platform that just produced an unusually clean, regulatory-validated win. But it is also a bet whose burden sits with future data the company has not yet reported. The margin of safety is thin: because the stock has already re-rated so far, a first-line or lung readout that is merely "good" rather than "transformative" gives the multiple little room to absorb disappointment.

Ruling

Bull on the business, cautious on the stock at this price. The product case is proven and the base is de-risked — the bear cannot credibly argue daraxonrasib doesn't work. But the $43 billion valuation already capitalizes the expansion thesis, so the incremental upside now depends on Phase 3 readouts that are a year or more away. The burden of proof sits with the bull's pipeline, not with the survival data that everyone has already seen.

The ruling flips on measurable, dated evidence. The single most important tripwire is the first-line pancreatic data — if RASolute 303 delivers a survival benefit in the direction of the second-line trial, the franchise thesis strengthens and the "stock ahead of itself" case weakens; a first-line result that is only incremental would expose how much of the run was borrowed from the future. Watch the zoldonrasib lung Phase 3 timelines, the resolution of the Erasca dispute, and the burn rate against that $3.9 billion cash cushion. Revolution hasn't lost anything it has already won. The question is whether investors paid in advance for wins that are still on the schedule.